相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New antibody drug treatments for lymphoma
Sam Mayes et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Bispecific antibodies engage T cells for antitumor immunotherapy
Bryan D. Choi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Bispecific Antibodies for Cancer Immunotherapy
Dafne Müller et al.
BIODRUGS (2010)
Glycosylation of Therapeutic Proteins An Effective Strategy to Optimize Efficacy
Ricardo J. Sola et al.
BIODRUGS (2010)
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Riad Abes et al.
BLOOD (2010)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Application of a novel bispecific antibody-based scaffold for optimal redirected T-cell killing of cancer cells
Paul A. Moore et al.
CANCER RESEARCH (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Naptumomab estafenatox: a new immunoconjugate
Matthew K. Robinson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Antibodies to watch in 2010
Janice M. Reichert
MABS (2010)
A modular IgG-scFv bispecific antibody topology
Kelly Davis Orcutt et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
Jonathan H. Davis et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Roland E. Kontermann
BIODRUGS (2009)
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
T. Schulze et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Engineered therapeutic antibodies with improved effector functions
Tsuguo Kubota et al.
CANCER SCIENCE (2009)
Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
Philippe Fournier et al.
EXPERT REVIEW OF VACCINES (2009)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives
Roland Stork et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
Ralf Lutterbuese et al.
JOURNAL OF IMMUNOTHERAPY (2009)
The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators
Nazzareno Dimasi et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
Jennifer S. Michaelson et al.
MABS (2009)
Bispecific antibodies for cancer therapy The light at the end of the tunnel?
Patrick Chames et al.
MABS (2009)
Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig™) molecules
Chengbin Wu et al.
MABS (2009)
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Royston Jefferis
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412
C. M. Dayan et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
When binding is enough: nonactivating antibody formats
Aran F. Labrijn et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Molecular engineering and design of therapeutic antibodies
Leonard G. Presta
CURRENT OPINION IN IMMUNOLOGY (2008)
Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins
Alain Beck et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2008)
Ertumaxomab: a trifunctional antibody for breast cancer treatment
Philipp Kiewe et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
Michael Stanglmaier et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies
Roland Stork et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Making autoantibodies safe
Christopher N. Scanlan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors
Matthew G. Fury et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3):: a phase I study
Martin Sebastian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
Alexander Burges et al.
CLINICAL CANCER RESEARCH (2007)
The impact of glycosylation on the biological function and structure of human immunoglobulins
James N. Arnold et al.
ANNUAL REVIEW OF IMMUNOLOGY (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence
Christoph Fiola et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
B Schlereth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Recombinant antibodies with T-cell receptor-like specificity: Novel tools to study MHC class I presentation
Galit Denkberg et al.
AUTOIMMUNITY REVIEWS (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
C Haas et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
The new face of bispecific antibodies: targeting cancer and much more
LG Lum et al.
EXPERIMENTAL HEMATOLOGY (2006)
Glycosylation of recombinant antibody therapeutics
R Jefferis
BIOTECHNOLOGY PROGRESS (2005)
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development
L Yan et al.
BIOTECHNIQUES (2005)
BiTEs: bispecific antibody constructs with unique anti-tumor activity
E Wolf et al.
DRUG DISCOVERY TODAY (2005)
Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
V Schirrmacher
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
C Haas et al.
VACCINE (2005)
Recombinant bispecific antibodies for cancer therapy
RE Kontermann
ACTA PHARMACOLOGICA SINICA (2005)
A revival of bispecific antibodies
P Kufer et al.
TRENDS IN BIOTECHNOLOGY (2004)
Complement function in mAb-mediated cancer immunotherapy
KA Gelderman et al.
TRENDS IN IMMUNOLOGY (2004)
Cancer immunotherapy: A treatment for the masses
JN Blattman et al.
SCIENCE (2004)
Effect of tetravalent bispecific CD19 x CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells
U Reusch et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
R Repp et al.
BRITISH JOURNAL OF CANCER (2003)
A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing
L Grosse-Hovest et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
T Dreier et al.
JOURNAL OF IMMUNOLOGY (2003)
Bispecific antibody conjugates in therapeutics
Y Cao et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
S Krapp et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma
P Borchmann et al.
BLOOD (2002)
Interaction sites on human IgG-Fc for FcγR:: current models
R Jefferis et al.
IMMUNOLOGY LETTERS (2002)
Improving the efficacy of antibody-based cancer therapies
P Carter
NATURE REVIEWS CANCER (2001)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEpCAM x αCD3)
R Riesenberg et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2001)
Intracellular functions of N-linked glycans
A Helenius et al.
SCIENCE (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
